Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634029 | 0.92 | MAPT (0.34) | MAPTCYP1A2LMNAMAPK1HTT | |
| SCHEMBL15499445 | 0.88 | MAPT (0.32) | MAPT | |
| SCHEMBL18538147 | 0.81 | MAPT (0.36) | MAPTCYP1A2LMNAMAPK1HTT | |
| SCHEMBL15728707 | 0.81 | MAPT (0.36) | MAPTCYP1A2 | |
| SCHEMBL15457901 | 0.79 | MAPT (0.54) | MAPTCYP1A2LMNAMAPK1HTT | |
| SCHEMBL18517331 | 0.79 | — | — | |
| SCHEMBL19634168 | 0.78 | MAPT (0.34) | MAPTCYP1A2 | |
| SCHEMBL16749937 | 0.76 | MAPT (0.31) | MAPT | |
| SCHEMBL10881985 | 0.75 | CYP1A2 (0.61) | MAPTCYP1A2LMNAMAPK1HTT | |
| SCHEMBL2901914 | 0.75 | CYP1A2 (0.61) | MAPTCYP1A2LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170335195-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170292072-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2017-10-12 | — | — | US | disclosed |
| US-9726933-B2 | Liquid-crystal displays and liquid-crystalline media having homeotropic alignment | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-20170044437-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170002269-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20160333270-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-11-17 | — | — | US | disclosed |
| US-20160319194-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160108318-A1 | LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20150205158-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150184077-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044437-A1 | LIQUID-CRYSTALLINE MEDIUM | VIM, COL2A1, COL1A1 | MAPT 737/4885CYP1A2 3394/4885LMNA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.